Abstract: Protein analogues of tissue plasminogen activator (tPA) are described. The analogues exhibit the proteolytic function of natural tPA and optionally fibrin binding activity, but are molecules, generally of lower molecular weight than natural tPA, designed for efficient expression in prokaryotic host cell systems. The analogues can comprise a catalytic fragment of tPA or a catalytic fragment of tPA linked to a polypeptide which stabilizes the catalytic fragment, provides for efficient expression of the fragment or confers a fibrin binding capability. Fibrin binding polypeptides can be a polypeptide fragments derived from tPA which embody the fibrin binding domain(s) of natural tPA or they can be an exogenous (non-tPA) polypeptides of eukaryotic or prokaryotic origin which exhibit fibrin binding affinity such as the antigen binding fragment of an antifibrin immunoglobulin or the B domain of protein A. Genetic constructs for expression of the analogues are also provided.

Abstract: Stable and ready to use liquid reagent for determining the glucose content in blood, comprising a glucose-oxidase free from catalase and a nonionic surface-active agent, such as, for example, the polyoxyethylene derivatives, hydroxypolyethylene ethoxydodecane, the lauryl ether of polyoxyethylene-glycol, as a stabilizer.

Abstract: The invention relates to a solution for controlling the performance of the ionic exchange chromatography column of HPLC apparatuses, and more particularly of the AUTO A1C HA 8110-8111 apparatus with a MICROPEARL S-F-W-A1C column, said solution being made up of a lyophilic hemolysate comprising hemoglobin, monobasic potassium phosphate, dibasic potassium phosphate, .alpha.-D-ribose, guanine, cytosine, thymine and uracil, and a solvent, for restoring the lyophilic hemolysate, comprising a nonionic surface active agent such as TRITON X-100, a bacteriostatic agent, such as for instance sodium azide, and water, and it also relates to a process for the production of said solution.

Abstract: Use of bromure d'otilonium, that it otilonii bromidum, for local applications in the gastrointestinal tract of the digestive system and related pharmaceutical formulation appropriate for such use, to obtain the arrest of the motility of the gastrointestinal tract in order to allow endoscopic manoeuvers for diagnostic and therapeutic purposes.

Abstract: A 2-substituted benzofuran derivative of general formula I or II ##STR1## in which R.sub.1 and R.sub.2, can be the same or different, and are a hydrogen atom, a halogen atom, an alkyl group containing 1 to 4 carbon atoms, an arylalkyl group, an aryl group, a hydroxyl group, an alkoxy group, or an NH.sub.2, NH-alkyl, N(alkyl).sub.2, NH(CO-alkyl), NH(CO-aryl) or NO.sub.2 group, or R.sub.1 and R.sub.2 can together form a ring of 5-8 carbon atoms; R.sub.3 is a hydrogen atom, an alkyl group containing 1 to 4 carbon atoms or an aryl group; R.sub.4 is a hydrogen atom, an alkyl group, an aryl or an arylalkyl group, R.sub.5 is a hydroxyl group, an alkoxy group, an OCO-alkyl, an OCO-aryl, OCOHN-alkyl or OCONH-aryl group, ##STR2## where n is a number between 1 and 4, R.sub.7 is a hydrogen atom or an alkyl group containing 1 to 4 carbon atoms, and R.sub.8 and R.sub.

Abstract: A pharmacologically active compound has the general formula ##STR1## in which R is a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms; R.sub.1 and R.sub.2, which can be different, represent a hydrogen atom, a hydroxyl group, an alkyl group, an alkoxy group, an arylalkyl group, or an arylalkoxy group, or can jointly represent an oxygen atom or a CHCOOR.sub.1 ' group where R.sub.1 ' is a hydrogen atom or an alkyl group; and R.sub.3 represents a hydrogen or halogen atom or an alkyl, NH.sub.2, NO.sub.2, NHCO-alkyl, NHCO-aryl, NHCONH-alkyl or NHCOHN-aryl group.These compounds act on the central nervous system and have an anti-convulsant sedative activity.

Abstract: The invention comprises: a derivative of 1-alkylamine-3-[4(p-alkyloxy-benzamide)phenoxy]-2-propanol of general formula I: ##STR1## where R.sub.1 is a linear or branched alkyl chain with 1 to 8 carbon atoms included, an alkenyl chain with 2 to 8 carbon atoms included, or an arylalkyl chain with 7 to 10 carbon atoms included, and R is a linear or branched alkyl group with 1 to 8 carbon atoms included;a compound as above, in an optically active form;pharmaceutically acceptable, non toxic salts of the above compounds;synthesis processes for obtaining the above compounds; anda pharmaceutical composition based on a compound as defined above.

Abstract: A 2-substituted benzofuran derivative of general formula I or II ##STR1## in which R.sub.1 and R.sub.2, can be the same or different, and are a hydrogen atom, a halogen atom, an alkyl group containing 1 to 4 carbon atoms, an arylalkyl group, an aryl group, a hydroxyl group, an alkoxy group, or an NH.sub.2, NH-alkyl, N(alkyl).sub.2, NH(CO-alkyl), NH(CO-aryl) or NO.sub.2 group, or R.sub.1 and R.sub.2 can together form a ring of 5-8 carbon atoms; R.sub.3 is a hydrogen atom, an alkyl group containing 1 to 4 carbon atoms or an aryl group; R.sub.4 is a hydrogen atom, an alkyl group, an aryl or an arylalkyl group, R.sub.5 is a hydroxyl group, an alkoxy group, an OCO-aryl an OCO-alkyl, OCONH-alkyl or OCONH-aryl group, ##STR2## where n is a number between 1 and 4, R.sub.7 is a hydrogen atom or an alkyl group containing 1 to 4 carbon atoms, and R.sub.8 and R.sub.

Abstract: A new compound 3(4-phenyl-1-piperazinio-1-yl)-1,2-propanediol 3(theophyllin-7-yl)-1-propanesulphonate, possesses antitussive action and is therefore usable in therapy. The compound is obtained by treating 3(theophyllin-7-yl)-1-propanesulphonic acid with 3(4-phenylpiperazin-1-yl)-1,2-propanediol in a suitable solvent.

Abstract: A compound for use as a normolipidemizer and/or a platelet anti-binder in therapy, and pharmaceutical compositions containing the compound.

Abstract: A compound having pharmacological properties comprising the structural formula ##STR1## wherein R is selected from the isopropyl, n-octyl, n-butyl or isobutyl groups; R.sub.1 is selected from the 1-naphthyloxymethyl, (2-allylphenoxy)-methyl, 4-nitrophenyl, {2-[(tetrahydrofurfuryl)oxy-]-phenoxy}-methyl, [4-(2-methoxyethyl)phenoxy]methyl, 4-isopropylthiophenyl, 4-acetaminophenoxymethyl groups; and R.sub.2 represents a hydrogen atom or a methyl group. A method for synthetizing the compound is also disclosed comprising the cyclization of aminoalcohol or halogenurethane.

Abstract: New compounds useful as spasmolytic agents are provided with the following formula: ##STR1## wherein n is either 2 or 3. In addition, salts of these new compounds are provided and are suitable for oral as well as parenteral administration to animals and man as spasmolytic agents. In compositions for oral and parenteral or rectal administration, from about 5 to about 40 mg of active ingredient per dosage unit is used. The bromide and iodide salts of these new compounds are especially useful.

Abstract: This invention relates to the use of 2-(1-chloro-2-yloxy) propionic acid and its derivatives having physiological activity, notably as antiphlogistics, analgesics, analgesics and anti-pyretics. The physiologically active compounds include esters and amides of the substituted propionic acid. The compounds can be presented in conventional pharmaceutical form, including the non-toxic, pharmaceutically acceptable salts thereof.